Skip to main content
TipRanks
Go Ultimate75% OFF

Sino Biopharmaceutical (SMZ1) AI Stock Analysis

0 Followers
DE:SMZ1

Sino Biopharmaceutical

(Frankfurt:SMZ1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Reaccelerating Revenue GrowthImproving top-line growth indicates stronger demand and commercialization across the medicine portfolio after several slower periods. If sustained, this momentum can broaden the revenue base, support operating leverage, and provide resources for continued investment in research, approvals, and market expansion.
Negative Factors
Falling Net ProfitabilityThe sharp decline in net margin shows that revenue growth is not translating into bottom-line earnings as efficiently as before. Persistent pressure could reduce reinvestment capacity, weaken returns on equity, and make future earnings less predictable even if the company maintains strong gross margins.

Sino Biopharmaceutical (SMZ1) vs. iShares MSCI Germany ETF (EWG)

-40%-30%-20%-10%0%10%20%DE:SMZ1-16.04%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 11.84B
Dividend Yield
1.99%
Average Volume (3M)
2,748
Price to Earnings (P/E)
34.9
Beta (1Y)
0.03
Revenue Growth
6.55%
EPS Growth
-35.88%
Country
Germany
Employees
22,838
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Sino Biopharmaceutical Business Overview & Revenue Model

Company Description

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicin...

Sino Biopharmaceutical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:SMZ1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1530HK:153082OutperformHKD 35.19B3.5430.16%1.80%101.73%249.15%
HK:1801HK:180163NeutralHKD 149.97B102.936.06%―42.64%9.67%
HK:2696HK:269657NeutralHKD 23.93B23.4320.41%―32.63%8.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:9926HK:992645NeutralHKD 58.26B-50.54-10.86%―42.47%-15.80%
HK:1877HK:187741NeutralHKD 27.62B-63.54-7.23%―35.82%54.40%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%DE:SMZ1HK:1801HK:1530HK:9926HK:1877HK:2696Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:SMZ1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:SMZ1Sino Biopharmaceutical0.62-0.14-18.35%
HK:1801Innovent Biologics85.80-3.85-4.29%
HK:15303SBio, Inc.13.86-17.85-56.29%
HK:9926Akeso, Inc.61.90-49.90-44.63%
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class H14.11-10.15-41.84%
HK:2696Shanghai Henlius Biotech, Inc. Class H43.88-20.57-31.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.